TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications to older adults. It recommends assessing function, nutrition and cognition before treatment, and pairing medication with supports such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a framework to help clinicians prescribe obesity medications, including GLP-1 drugs, to older adults with attention to age-related risks and individual priorities. The case-based guidance, published in the Journal of the American Geriatrics Society, calls for evaluating functional status, nutrition and cognition before treatment and considering supportive measures alongside medication.
Developed by the AGS Healthy Aging Special Interest Group, the paper applies the society’s Geriatrics 5Ms Framework—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapies. Its case-based format is intended to give clinicians a practical way to weigh treatment decisions for older patients rather than treating weight loss as the only goal.
The authors say that prescribing decisions should account for frailty, sarcopenia and the possibility of losing lean muscle, as well as risks of malnutrition and dehydration. They recommend pretreatment assessment of a patient’s functional status, nutritional adequacy and cognitive impairment. The report also advises pairing medication with measures such as resistance training and sufficient dietary protein.
For some patients, the paper says, care may be best coordinated by a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The report presents these as considerations for clinicians; it does not establish that every older adult receiving obesity medication needs every listed service.
Balancing Weight Loss With Muscle Health
The framework addresses a clinical gap: according to the report, older adults are underrepresented in clinical trials of obesity medications. That means evidence about benefits and risks may not fully reflect the needs of older patients, for whom changes in strength, mobility, nutrition and hydration can carry particular importance.
Obesity medications may offer benefits for weight management, glycemic control and other health conditions, the report says. The framework’s emphasis is that those potential benefits should be weighed alongside a person’s broader health and priorities. For readers and caregivers, the practical message is that a prescription may be one part of care, with nutrition, exercise capacity and daily functioning also relevant to the treatment plan.
The 5Ms approach places “Matters Most” alongside medical and functional considerations, directing attention to what an individual patient values. That can help structure a clinician-patient discussion, but the article does not report new clinical trial results or prove that the framework improves outcomes.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Levoit Core 600S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The AGS framework adapts an existing geriatrics approach to incretin therapy, a category that includes GLP-1 medications. Its five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most. Together, they prompt clinicians to consider cognitive health, movement and function, a patient’s other medicines and health conditions, and the outcomes that matter to the patient.
The report is a clinical guidance paper organized around cases, not a medication approval announcement or a new drug trial. Its authors focus on how clinicians might use the 5Ms when considering obesity medicines for older adults and on the assessments and co-interventions they believe should accompany prescribing.
The paper, by Elias M. Wisdom and colleagues, was published in the Journal of the American Geriatrics Society in 2026. Its DOI is 10.1111/jgs.70769. The source report does not provide trial data, prescribing rates or a comparison of outcomes between patients who do and do not follow the framework.
“Mind, Mobility, Medications, Multicomplexity, and Matters Most”
— The American Geriatrics Society framework, as summarized in the report
Evidence Gaps in Older Patients
The source report does not specify how much older adults were underrepresented in the trials, which medications or patient groups have the strongest evidence, or whether the proposed framework has been tested in routine care. It also gives no quantified estimates of the risks of muscle loss, malnutrition or dehydration in older patients receiving these drugs.
It remains unclear whether using the framework changes prescribing decisions or improves health outcomes. The paper offers clinical considerations and recommendations, not proof that a particular assessment schedule, exercise plan or team structure is effective for every patient. Decisions about treatment and monitoring remain specific to the individual and should be made with qualified clinicians.
How Clinicians May Use the Guidance
The framework is now available to clinicians through its publication in the Journal of the American Geriatrics Society. The report does not announce a rollout, implementation deadline or follow-up study. Its immediate role is to provide a case-based structure for conversations and assessments when clinicians consider obesity medications for older adults.
Further research would be needed to show how well the approach works in practice, including whether it helps preserve function or address nutrition-related risks while supporting treatment goals. For patients considering these medicines, the paper points to topics to discuss with a clinician—such as mobility, diet, cognition and personal priorities—rather than offering individualized medical advice.
Key Questions
What did the American Geriatrics Society publish?
It published a case-based framework for clinicians considering obesity medications in older adults, applying the Geriatrics 5Ms to incretin therapy.
Which risks does the framework ask clinicians to consider?
The paper highlights frailty, sarcopenia, lean muscle loss, malnutrition and dehydration, along with a patient’s functional and cognitive status.
Does the framework recommend medication alone?
No. The authors recommend considering supports such as resistance training and adequate dietary protein alongside treatment. Some patients may benefit from team-based care, according to the paper.
Does the report show that the framework improves outcomes?
The source report describes a guidance paper, not an outcomes trial. It does not establish whether using the framework improves patient results or quantify the effects of its recommendations.
Source: medicalxpress.com
